Kidswell Bio Corporation
4584
Rank in Stocks
#23131
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the... Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Share Price
$0.91147031
Last synced: 2026-11-10
Market Cap
$45.24M
Change (1 day)
2.86%
Change (1 year)
-43.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kidswell Bio Corporation (4584)
Category
Healthcare
Operating Margin for Kidswell Bio Corporation (4584)
Operating Margin as of November 2026 TTM: -1.74%
According to Kidswell Bio Corporation's latest financial reports, its current operating margin (TTM) is -1.74%. At the end of 2025 the company had an operating margin of 0.55%.
Operating Margin history for Kidswell Bio Corporation from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1.74% | -416.36% |
| 2025 | 0.55% | -101.00% |
| 2024 | -54.93% | 176.86% |
| 2023 | -19.84% | -52.18% |
| 2022 | -41.49% | -57.36% |
| 2021 | -97.31% | -9.81% |
| 2020 | -107.89% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -122.18% |
US
|
|
| -149.01% | -14.36% |
US
|
|
| 25.57% | -114.70% |
AU
|
|
| 31.23% | -117.95% |
BE
|
|
| 29.35% | -116.87% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kidswell Bio Corporation's operating margin
What is Kidswell Bio Corporation's operating margin?
Kidswell Bio Corporation's operating margin is -1.74%, as of Nov 2026.
What was Kidswell Bio Corporation's operating margin in 2025?
In 2025, Kidswell Bio Corporation's operating margin was 0.55%, compared with -54.93% in 2024.
How has Kidswell Bio Corporation's operating margin changed since 2020?
From 2020 to 2025, Kidswell Bio Corporation's operating margin was highest in 2025 (0.55%) and lowest in 2020 (-107.89%).
How does Kidswell Bio Corporation's operating margin compare with similar companies?
Kidswell Bio Corporation's operating margin (-1.74%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.